Videopodcast: Krebsforschung - Grund zur Hoffnung? | Lanz + Precht, Folge 268

Main Ideas

1. Cancer research is entering a more promising phase

• Molecular biologist Hanna Heikenwälder says researchers have reached a point where they have a clearer sense of what needs to be done. The main challenge is increasingly how to implement promising approaches, fund them, and make them available in practice.
• Advances in tumor sequencing and artificial intelligence (AI) may help researchers interpret the vast range of changes found in cancer cells and identify which ones matter for treatment.
• The aim is not necessarily to eliminate cancer, which Heikenwälder considers unrealistic, but to reduce the chances that people suffer or die from it—especially through earlier detection and more effective, less harmful treatment.

2. Cancer develops through a long process

• Cancer usually does not appear all at once. It often develops over years or decades as cells accumulate genetic changes.
• Most mutations do not cause cancer. A small number of “driver” mutations can give a cell a growth advantage, allowing it to spread and acquire further changes.
• Cancer cells are ordinary body cells that have changed; they are not consciously acting or behaving maliciously. Their spread is described as evolution on a small scale.
• Mutations are part of life and evolution, so the existence of cancer cannot be entirely prevented. The immune system normally detects and removes many abnormal or aging cells, but that protection can become less effective over time.

3. Treatment is becoming more targeted and individualized

• Traditional chemotherapy works broadly by damaging rapidly dividing cells. This can also harm healthy cells, causing side effects such as nausea, hair loss, and a weakened immune system.
• Newer targeted therapies seek changes specific to a tumor and attack those while causing less damage to other cells. Examples discussed include tyrosine kinase inhibitors and a KRAS inhibitor for pancreatic cancer.
• The KRAS treatment discussed reportedly doubled survival time in patients with advanced pancreatic tumors, from roughly nine months to 18 months. The speakers describe this as a meaningful advance for an aggressive cancer, while acknowledging that the absolute survival time remains limited.
• Because tumors differ—even when they occur in the same organ—treatment may need to be tailored to each patient. This is called personalized medicine and may involve combinations of therapies rather than one universal drug.
• Personalized medicine requires extensive patient data. Tracking treatment outcomes can help researchers learn which tumor features respond to which approaches, but this requires major investment and better coordination between hospitals and research systems.

4. Cancer-directed mRNA therapy is different from preventive vaccination

• The mRNA cancer therapies discussed are treatments, not preventive vaccines like those against viruses that can later cause cancer.
• In the approach described, a tumor is sequenced and compared with healthy tissue. Information about tumor-specific features is then used to help direct the patient’s immune system toward that tumor.
• These therapies may be combined with checkpoint inhibitors, which ease some of the immune system’s restraints so it can attack cancer more effectively.
• The speakers also stress that the HPV vaccine is not only relevant to cervical cancer or to women. HPV can cause cancers affecting several mucous membranes, including cancers of the mouth and throat, penis, and anus.

5. Prevention and early detection remain crucial

Heikenwälder emphasizes that practical, evidence-based measures matter more than expensive supplements or complicated “anti-cancer” regimens. Her recommendations include:

• Do not smoke.
• Avoid alcohol.
• Avoid excessive sun exposure.
• Maintain a healthy body weight. The discussion identifies obesity as a major cancer risk factor.
• Move regularly. Everyday physical activity counts; it does not need to involve costly equipment or intense training.
• Attend recommended preventive check-ups. Cancer is often easier to treat when detected early.
• Get vaccinated where appropriate, including against HPV.
• Eat sensibly without becoming extreme. The guest argues against the idea of a special “anti-cancer diet.” She says that sugar itself is not carcinogenic, while long-term excessive consumption can contribute to obesity and metabolic problems associated with cancer risk.
• Avoid panic and perfectionism. The advice is to follow healthy habits most of the time rather than fear every deviation or become preoccupied with eating “the wrong” thing.

The discussion also notes that weight-loss medication may be an option for some people with severe obesity, but it can have side effects, and its long-term use was described as still relatively new. Heikenwälder presents movement and dietary changes as preferable where feasible, while acknowledging that medication may help some people take an initial step.

6. Stress may affect health, but the evidence is complicated

• The speakers discuss possible links between chronic stress, the immune system, and cancer. Heikenwälder cautions that it is difficult to establish a direct link because stress can also change people’s behavior, including whether they exercise, drink, or seek medical care.
• Short-term stress may temporarily activate immune responses, while chronic stress—particularly social stress—can be harmful to immune function. Much of the evidence discussed comes from animal studies, so direct conclusions about humans are limited.
• One especially practical concern is that stressed people may delay medical appointments or skip preventive screening, potentially allowing cancer to be detected later.

7. Aging, cancer, and comparisons across species

• Cancer risk and aging are connected in part because genetic changes accumulate over time and the immune system ages.
• The speakers discuss Peto’s paradox: large or long-lived animals do not appear to develop cancer at the vastly higher rates one might expect from their size or lifespan. Possible explanations include slower metabolism in some species and protective mechanisms, such as extra copies of the p53 gene in elephants.
• Cancer-resistant animals, including naked mole-rats, may offer useful research clues. These findings are experimental and do not yet establish treatments for people.
• Heikenwälder warns against claims that supplements or “longevity” routines can make people live indefinitely. Epigenetic clocks are currently biomarkers; researchers do not yet fully understand how they work or how to manipulate them safely.
• She argues that ordinary measures such as exercise, maintaining a healthy weight, and avoiding chronic disease are better-supported ways to promote health than taking large numbers of poorly understood substances.

8. Data, AI, and ethical questions

• AI could help identify patterns in medical images, blood tests, and tumor data, potentially allowing more accurate diagnoses and treatment recommendations.
• The long-term ambition described is for these tools to become inexpensive and usable in less-resourced regions, possibly with relatively simple tests or imaging.
• Heikenwälder says Europe and Germany face obstacles because hospital IT systems are fragmented and access to large, connected datasets is more limited than in the United States and China.
• Precht argues that anonymized medical data should be distinguished from personally identifiable data: anonymized information can support research without revealing an individual’s identity.
• The broader ethical issue is how to balance privacy with the potential benefits of sharing data to improve treatment.

Speakers and Sources Featured

Speakers

• Markus Lanz — host
• Richard David Precht — host and philosopher
• Hanna Heikenwälder — molecular biologist and cancer researcher, discussing research planning and personalized medicine

Named Individuals and Sources Referred To

• Michael Baumann — Heidelberg oncologist and cancer researcher, cited by Lanz in connection with personalized cancer treatment.
• Brian Johnson — Silicon Valley investor mentioned as an example of extreme longevity practices.
• Unspecified studies and researchers — discussed in relation to stress, cancer, animal models, obesity, immune aging, and other topics.
• Peto’s paradox — the scientific concept discussed in relation to cancer rates across animals of different sizes and lifespans.